Crowd counting is an effective tool for situational awareness in public places. Automated crowd counting using images and videos is an interesting yet challenging problem that has gained significant attention in computer vision. Over the past few years, various deep learning methods have been developed to achieve state-of-the-art performance. The methods evolved over time vary in many aspects such as model architecture, input pipeline, learning paradigm, computational complexity, and accuracy gains etc. In this paper, we present a systematic and comprehensive review of the most significant contributions in the area of crowd counting. Although few surveys exist on the topic, our survey is most up-to date and different in several aspects. First, it provides a more meaningful categorization of the most significant contributions by model architectures, learning methods (i.e., loss functions), and evaluation methods (i.e., evaluation metrics). We chose prominent and distinct works and excluded similar works. We also sort the well-known crowd counting models by their performance over benchmark datasets. We believe that this survey can be a good resource for novice researchers to understand the progressive developments and contributions over time and the current state-of-the-art.

Artificial intelligence (AI) is concretely reshaping the landscape and horizons of oncology, opening new important opportunities for improving the management of cancer patients. Analysing the AI-based devices that have already obtained the official approval by the Federal Drug Administration (FDA), here we show that cancer diagnostics is the oncology-related area in which AI is already entered with the largest impact into clinical practice. Furthermore, breast, lung and prostate cancers represent the specific cancer types that now are experiencing more advantages from AI-based devices. The future perspectives of AI in oncology are discussed: the creation of multidisciplinary platforms, the comprehension of the importance of all neoplasms, including rare tumours and the continuous support for guaranteeing its growth represent in this time the most important challenges for finalising the ‘AI-revolution’ in oncology.